PATENT CLAIM ANALYSIS

Application Number: 15513112
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2018-09
Patent Classification: ["514", "262100"]

Abstract:
Disclosed are methods for treating autism spectrum disorders and/or anxiety disorders by administering certain NR2B subunit-selective NMDA (N methyl-D aspartate) antagonists. Anxiety disorders include agoraphobia (with or without panic disorder), generalized anxiety disorder (GAD), social anxiety disorder (SAD), panic disorder (PD), post-traumatic stress disorder (PTSD) and obsessive-compulsive disorder (OCD).

Claim (Index 30):
The method of  claim 26 , wherein the NR2B subunit-selective NMDA antagonist is (3R,4S)-4-methylbenzyl 3-fluoro-4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate: or a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 52.0
- Percentile: 96.0
- Lexical Diversity: 1.60465
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15538015', '09969317', '11933056', '16046332', '11535455']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7865883056495244
- 35 USC 102 Novelty (BERT): 0.5196947509913857
- Combined Prediction Score: 0.7598989501837106
- Mean Citation Score: 285.661044
- Max Citation Score: 318.88898
- Similarity Product: 244.453643600626

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test